CIA
SZYM

Capital Impact Advisors’s SOLAZYME INC COM STK (DE) SZYM Stock Holding History

Capital Impact Advisors’s Portfolio SZYM Stock Details SZYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,269
Closed -$114 – 224
2014
Q3 		$114 Hold
15,269
– – ﹤0.01% 204
2014
Q2 		$180K Buy
+15,269
New +$163K 0.14% 108

Other funds holding SZYM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T
Tahithromos New York $71.9M AUM 0.24% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Impact Advisors's SZYM Position: Q4 2014 in Review

Capital Impact Advisors sold out of SOLAZYME INC COM STK (DE) (SZYM) in Q4 2014, closing a stake of 15,269 shares — an estimated $114 sold.

Capital Impact Advisors first reported a position in SZYM in Q2 2014 and held it in 2 quarters. The position peaked at $180K in Q2 2014. 114 funds tracked by Wall St. Rank hold SZYM as of Q4 2014.

  • Capital Impact Advisors reported no remaining SOLAZYME INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Capital Impact Advisors sold 15,269 SOLAZYME INC COM STK (DE) shares in Q4 2014, an estimated $114.
  • Capital Impact Advisors first reported a position in SOLAZYME INC COM STK (DE) in Q2 2014 and held it in 2 quarters.
  • Capital Impact Advisors's SOLAZYME INC COM STK (DE) position peaked at $180K in Q2 2014.
  • 114 funds tracked by Wall St. Rank held SOLAZYME INC COM STK (DE) as of Q4 2014.

Based on Capital Impact Advisors's 13F filing for Q4 2014, filed 25 Feb 2015.